© 2024 Medifast, Inc. All Rights Reserved. Medifast Q4 2023 Highlights • Q4 2023 revenue and EPS within guidance range Medifast® Q4 2023 Earnings Presentation © 2024 Medifast, Inc. All Rights Reserved. ▼ MEDIFAST. ▒《OPTAVIA。 Safe Harbor Statement 2 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These fo ...

Medifast (MED) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $3.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.10%. A quarter ago, it was expected that this weight-loss company would post earnings of $1.02 per share when it actually produced earnings of $2.12, delivering a surprise of 107.84%.Over the last four quarters, the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to____________. Commission file number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-3714405 | | ...

Medifast, Inc. (MED) is likely to register a top-and-bottom-line decline when it reports fourth-quarter 2023 earnings on Feb 20. The Zacks Consensus Estimate for revenues is pegged at nearly $174 million, suggesting a decrease of 48.4% from the prior-year quarter’s reported figure.The consensus mark for quarterly earnings has remained unchanged in the past 30 days at 99 cents per share, which indicates a decline of 73.2% from the year-ago quarter’s reported figure. MED has a trailing four-quarter earnings s ...

Medifast, Inc. (NYSE:MED) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Steven Zenker - Vice President of Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Linda Bolton Weiser - D.A. Davidson Jim Salera - Stephens Inc. Doug Lane - Water Tower Research Operator Greetings. Welcome to the Medifast Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-onl ...

© 2023 Medifast, Inc. All Rights Reserved. $236M REVENUE $158M CASH & CASH EQUIVALENTS AND INVESTMENTS 2 Continue to invest in growth initiatives that are expected to benefit results in 2024 and beyond | --- | --- | --- | --- | |-----------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-371440 ...

Medifast, Inc. (NYSE:MED) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Steve Zenker - VP of IR Dan Chard - Chairman and CEO Jim Maloney - CFO Conference Call Participants Linda Bolton-Weiser - D.A. Davidson Operator Good afternoon, and welcome to the Medifast Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would ...

1 Q3 Guidance reflects continued customer acquisition challenges from the macro economic environment and GLP-1 drugs 2 Continue to invest in growth initiatives that are expected to benefit results in 2024 and beyond 3 Continue to reduce expenses through F4F initiative - optimization of procurement, distribution, co-manufacturing, and R&D activities 4 Launch of OPTAVIA ACTIVE™ product line in September to Customers will tap into a much larger addressable market than the current structured weight loss market ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. | Title of each class | Trading Symbol | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value ...